Page 44 - Read Online

155. Wells SA, Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA,
M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir Shah MH, Ali SM, Stephens PJ. Comprehensive genomic profiling
P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally of clinically advanced medullary thyroid carcinoma. Oncology
advanced or metastatic medullary thyroid cancer: a randomized, 2016;90:339-46.
double-blind phase III trial. J Clin Oncol 2012;30:134-41. 165. Zhu W, Hai T, Ye L, Cote GJ. Medullary thyroid carcinoma cell lines
156. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, contain a self-renewing CD133+ population that is dependent on ret
Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle proto-oncogene activity. J Clin Endocrinol Metab 2010;95:439-44.
B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, 166. Kucerova L, Feketeova L, Kozovska Z, Poturnajova M, Matuskova
Sherman SI. Cabozantinib in progressive medullary thyroid cancer. M, Nencka R, Babal P. In vivo 5FU-exposed human medullary
J Clin Oncol 2013;31:3639-46. thyroid carcinoma cells contain a chemoresistant CD133+ tumor-
157. Spitzweg C, Morris JC, Bible KC. New drugs for medullary thyroid initiating cell subset. Thyroid 2014;24:520-32.
cancer: new promises? Endocr Relat Cancer 201610.1530/ERC- 167. Tang M, Hou YL, Kang QQ, Chen XY, Duan LQ, Shu J, Li SL, Hu
16-0104. XL, Peng ZP. All-trans-retinoic acid promotes iodine uptake via up-
158. Cai J, Li L, Ye L, Jiang X, Shen L, Gao Z, Fang W, Huang F, Su T, regulating the sodium iodide symporter in medullary thyroid cancer
Zhou Y, Wang W, Ning G. Exome sequencing reveals mutant genes stem cells. Asian Pac J Cancer Prev 2014;15:1859-62.
with low penetrance involved in MEN2A-associated tumorigenesis. 168. Bi Y, Meng Y, Wu H, Cui Q, Luo Y, Xue X. Expression of the
Endocr Relat Cancer 2015;22:23-33. potential cancer stem cell markers CD133 and CD44 in medullary
159. Smith J, Read ML, Hoffman J, Brown R, Bradshaw B, Campbell thyroid carcinoma: A ten-year follow-up and prognostic analysis. J
C, Cole T, Navas JD, Eatock F, Gundara JS, Lian E, McMullan D, Surg Oncol 2016;113:144-51.
Morgan NV, Mulligan L, Morrison PJ, Robledo M, Simpson MA, 169. Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H. Effects of
Smith VE, Stewart S, Trembath RC, Sidhu S, Togneri FS, Wake the histone deacetylase inhibitor valproic acid on Notch signalling
NC, Wallis Y, Watkinson JC, Maher ER, McCabe CJ, Woodward in human neuroblastoma cells. Br J Cancer 2005;92:751-9.
ER. Germline ESR2 mutation predisposes to medullary thyroid 170. Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR,
carcinoma and causes up-regulation of RET expression. Hum Mol Kunnimalaiyaan M, Chen H. Valproic acid activates Notch1
Genet 2016;25:1836-45. signaling and induces apoptosis in medullary thyroid cancer cells.
160. Jonsson P, Katchy A, Williams C. Support of a bi-faceted role of Ann Surg 2008;247:1036-40.
estrogen receptor beta (ERbeta) in ERalpha-positive breast cancer 171. Jaskula-Sztul R, Pisarnturakit P, Landowski M, Chen H,
cells. Endocr Relat Cancer 2014;21:143-60. Kunnimalaiyaan M. Expression of the active Notch1 decreases
161. Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho KK, MTC tumor growth in vivo. J Surg Res 2011;171:23-7.
Coombes RC, Poutanen M, Makela SI, El-Bahrawy M, Speirs V, 172. Jaskula-Sztul R, Eide J, Tesfazghi S, Dammalapati A, Harrison
Lam EW. ERbeta1 represses FOXM1 expression through targeting AD, Yu XM, Scheinebeck C, Winston-McPherson G, Kupcho KR,
ERalpha to control cell proliferation in breast cancer. Am J Pathol Robers MB, Hundal AK, Tang W, Chen H. Tumor-suppressor role
2011;179:1148-56. of Notch3 in medullary thyroid carcinoma revealed by genetic and
162. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson pharmacological induction. Mol Cancer Ther 2015;14:499-512.
JA. A genome-wide study of the repressive effects of estrogen 173. Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H.
receptor beta on estrogen receptor alpha signaling in breast cancer Resveratrol induces Notch2-mediated apoptosis and suppression
cells. Oncogene 2008;27:1019-32. of neuroendocrine markers in medullary thyroid cancer. Ann Surg
163. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of Oncol 2011;18:1506-11.
estrogen receptor beta on gene networks regulated by estrogen receptor 174. Tesfazghi S, Eide J, Dammalapati A, Korlesky C, Wyche TP, Bugni
alpha in breast cancer cells. Endocrinology 2006;147:4831-42. TS, Chen H, Jaskula-Sztul R. Thiocoraline alters neuroendocrine
164. Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, phenotype and activates the Notch pathway in MTC-TT cell line.
Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia Cancer Med 2013;2:734-43.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦ 293